title: Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.
abstract: Nephrotic syndrome results in hyperlipidemia and profound alterations in lipid and lipoprotein metabolism. Serum cholesterol, triglycerides, apolipoprotein B (apoB)-containing lipoproteins (very low-density lipoprotein [VLDL], immediate-density lipoprotein [IDL], and low-density lipoprotein [LDL]), lipoprotein(a) (Lp[a]), and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are increased in nephrotic syndrome. This is accompanied by significant changes in the composition of various lipoproteins including their cholesterol-to-triglyceride, free cholesterol-to-cholesterol ester, and phospholipid-to-protein ratios. These abnormalities are mediated by changes in the expression and activities of the key proteins involved in the biosynthesis, transport, remodeling, and catabolism of lipids and lipoproteins including apoproteins A, B, C, and E; 3-hydroxy-3-methylglutaryl-coenzyme A reductase; fatty acid synthase; LDL receptor; lecithin cholesteryl ester acyltransferase; acyl coenzyme A cholesterol acyltransferase; HDL docking receptor (scavenger receptor class B, type 1 [SR-B1]); HDL endocytic receptor; lipoprotein lipase; and hepatic lipase, among others. The disorders of lipid and lipoprotein metabolism in nephrotic syndrome contribute to the development and progression of cardiovascular and kidney disease. In addition, by limiting delivery of lipid fuel to the muscles for generation of energy and to the adipose tissues for storage of energy, changes in lipid metabolism contribute to the reduction of body mass and impaired exercise capacity. This article provides an overview of the mechanisms, consequences, and treatment of lipid disorders in nephrotic syndrome.
authors.affiliation: Division of Nephrology and Hypertension, Departments of Medicine, Physiology, and Biophysics, University of California, Irvine, Irvine, California. Electronic address: ndvaziri@uci.edu.
authors.forename: Nosratola D
authors.initials: ND
authors.lastname: Vaziri
mesh_terms: D002784:Cholesterol / Q000097:blood / Q000378:metabolism*; D003404:Creatinine / Q000652:urine; D050171:Dyslipidemias / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D008049:Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood / Q000378:metabolism*; D008099:Liver / Q000201:enzymology; D009404:Nephrotic Syndrome / Q000097:blood / Q000150:complications* / Q000378:metabolism / Q000652:urine; D011507:Proteinuria / Q000209:etiology; D018110:Receptors, Lipoprotein / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
chemical_list: C504173:LIPC protein, human; D008074:Lipoproteins; D018110:Receptors, Lipoprotein; D014280:Triglycerides; D002784:Cholesterol; D003404:Creatinine; D008049:Lipase
keywords: atherosclerosis; chronic kidney disease; hyperlipidemia; nephrotic syndrome; proteinuria; statins